Marko Ravic, Ivan Srejovic, Jovana Novakovic, Marijana Andjic, Jasmina Sretenovic, Maja Muric, Marina Nikolic, Sergey Bolevich, Kirill Alekseevich Kasabov, Vladimir Petrovich Fisenko, Aleksandra Stojanovic, Vladimir Jakovljevic
Metabolic syndrome (MetS) represents an important factor that increases the risk of myocardial infarction, and more severe complications. Glucagon Like Peptide-1 Receptor Agonists (GLP-1RAs) exhibit cardioprotective potential, but their efficacy in MetS-related myocardial dysfunction has not been fully explored. Therefore, we aimed to assess the effects of exenatide and dulaglutide on heart function and redox balance in MetS-induced rats. Twenty-four Wistar albino rats with induced MetS were divided into three groups: MetS, exenatide-treated (5 µg/kg), dulaglutide-treated (0...
April 19, 2024: Pharmaceuticals